RT Journal Article
T1 Transcatheter Aortic Valve Replacement for Residual Lesion of the Aortic Valve Following "Healed" Infective Endocarditis.
A1 Santos-Martínez, Sandra
A1 Alkhodair, Abdullah
A1 Nombela-Franco, Luis
A1 Saia, Francesco
A1 Muñoz-García, Antonio J
A1 Gutiérrez, Enrique
A1 Regueiro, Ander
A1 Jimenez-Diaz, Victor A
A1 Rivero, Fernando
A1 Romaguera, Rafael
A1 Gómez-Herrero, Javier
A1 Rodriguez-Gabella, Tania
A1 Sathananthan, Janarthanan
A1 Gómez Salvador, Itziar
A1 Carrasco-Moraleja, Manuel
A1 Rodés-Cabau, Josep
A1 Webb, John
A1 López, Javier
A1 San Román, J Alberto
A1 Amat-Santos, Ignacio J
K1 TAVR
K1 aortic prosthesis
K1 high surgical risk
K1 infective endocarditis
AB This study aimed to evaluate the safety and mid-term efficacy of transcatheter aortic valve replacement (TAVR) in the setting of aortic valve (AV) infective endocarditis (IE) with residual lesion despite successful antibiotic treatment. Patients with AV-IE presenting residual lesion despite successful antibiotic treatment are often rejected for cardiac surgery due to high-risk. The use of TAVR following IE is not recommended. This was a multicenter retrospective study across 10 centers, gathering baseline, in-hospital, and 1-year follow-up characteristics of patients with healed AV-IE treated with TAVR. Matched comparison according to sex, EuroSCORE, chronic kidney disease, left ventricular function, prosthesis type, and valve-in-valve procedure was performed with a cohort of patients free of prior IE treated with TAVR (46 pairs). Among 2,920 patients treated with TAVR, 54 (1.8%) presented with prior AV-IE with residual valvular lesion and healed infection. They had a higher rate of multivalvular disease and greater surgical risk scores. A previous valvular prosthesis was more frequent than a native valve (50% vs. 7.5%; p  TAVR is a safe therapeutic alternative for residual valvular lesion after successfully healed AV-IE. At 1-year follow-up, the risk of IE relapse was low and mortality rate did not differ from TAVR patients free of prior IE, but one-fourth presented with significant aortic regurgitation and >50% required re-admission.
YR 2020
FD 2020
LK http://hdl.handle.net/10668/16241
UL http://hdl.handle.net/10668/16241
LA en
DS RISalud
RD Jun 1, 2025